February 2022 – Policy & Medicine

Industry Calls for Further Clarity and Flexibility on RWD for Regulatory Decision-Making

Online Course Updates Allergists and Dermatologists on Latest in Atopic Dermatitis Management

Generic Drugs Reduce Per Capita Spending on Prescription Drugs

DOJ Announces $5.6 Billion in False Claims Act Settlements and Judgments in FY 2021

Eli Lilly is the Recipient of the First OPDP Untitled Letter of 2022

ONC Publishes Trusted Exchange Framework and the Common Agreement

CMS Releases 2023 Medicare Advantage and Part D Advance Notice

Online CME Program on Mycophenolate REMS includes Easy to Follow Book Format and Patient Education in Multiple Languages

Policy and Medicine Compliance Update February 2022 Issue Focuses on Emerging Trends in Compliance Plus 340B and FTC Litigation

Study Finds IT MATTTRs Provider Education an Effective Resource for Increasing Buprenorphine Treatment